Endpoints News

ASCO roundup: the new Ibrance, and why Gilead bought Tubulis		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

22 May, 2026

LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.

spotlight

Exclusive: Inside the covert campaign to push out FDA Commissioner Marty Makary

news

Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop

Ibrance's would-be successors, the data that helped sell Tubulis to Gilead and more at ASCO

Peer Review

Amgen CFO to follow David Reese into retirement; Josh Smiley is out at Zai Lab

May 28

11:30 am ET

From signal to strategy: The future of systemic viral immunotherapy in GI tumors and Oncolytics Biotech

in case you missed it

Incyte signs AI deals with Genesis and Edison, tapping its experimental data

BioMarin to seek further approval of Voxzogo in form of short stature

Lilly’s triple agonist still leads among late-stage obesity assets

Acting head of US NIH infectious disease institute has left, senators say

FDA Plans Rare Advisory Hearing to Debate Moderna’s Flu Shot

Monday is Memorial Day, a public holiday in the US, and Endpoints won't be sending our usual newsletters. We'll return on Tuesday, May 26. Have a great long weekend!

Elizabeth Cairns

Senior Biopharma Journalist, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com